Tweets
#POS0660
Integrated data analyses of the DARWIN, and FINCH studies (7 in total) on #filgotinib and #statin use:
> Around 10% of 4057 RA patients used statins at baseline
> Muscle related AE were rare with no clear relation to filgotinib
#EULAR2021 @RheumNow
Paul Studenic @Stiddyo ( View Tweet )
5 years 2 months ago
#POS0930
@XBaraliakos investigated baseline predictors differential treatment effect on ASAS20 response at week 12 of 473 ax-PsA using MAXIMISE trial data (#Secukinumab)
-> Only nail dystrophy
OR: 3 (150mg)
OR: 5 (300mg)
🤔But why?
#EULAR2021 @RheumNow https://t.co/srb6jGgBqe
Paul Studenic @Stiddyo ( View Tweet )
5 years 2 months ago
#EULAR2021 live might close but there is still on demand until the 4th of July.
Interested in my poster: showing that quality of life in at-risk for #RA individuals is reduced but still differ from RA.. have a look at #POS1441
New insights in "pre-disease phase"
@RheumNow https://t.co/xtyEgElYkX
Paul Studenic @Stiddyo ( View Tweet )
5 years 2 months ago
What kind of trials would help you in making a decision which DMARD to choose if a patient is not meeting #T2T goal?
#EULAR2021 @RheumNow
Paul Studenic @Stiddyo ( View Tweet )
5 years 2 months ago
Norwegian Cardio-Rheuma register review of PsA incidence 32/100,000 pyrs, 28 among 🚹 & 35 among 🚺,highest in 50-59 yo pts. MTX initiated >50% PsA cases w/in 1 yr from index date, 19% used biologic DMARDs w/in 2 yrs. Abstract #POS1041 #EULAR2021 @RheumNow https://t.co/2PGVfeoFV9 https://t.co/CT9WTzcdcc
Dr. Rachel Tate @uptoTate ( View Tweet )
5 years 2 months ago
Italian PsABio cohort study: UST ⬆️ overall persistence vs TNFi, especially in females, in monotherapy, BMI <25 or >30 kg/m2, & UST as 2nd-line tx. At 1 year, both UST & TNFi pts showed similar cDAPSA & MDA/VLDA. Abstract #POS1021 #EULAR2021 @RheumNow https://t.co/DGRXmPiTiD https://t.co/s7zMuSBEWt
Dr. Rachel Tate @uptoTate ( View Tweet )
5 years 2 months ago
More data from @rheum_covid presented by @mugartegil showing prognostic factors in patients with SLE & COVID-19
Factors related with poor prognosis:
-Male, Age, Comorbidities
-Time period (1st wave)
-GC doses
-Disease activity
- No enough data for RTX or Beli
#EULAR2021
#LUPUS https://t.co/ts8QsyR5KA
José A. Gómez Puerta @DrGomezPuerta ( View Tweet )
5 years 2 months ago
What is the highest level reaction you have seen to COVID vaccine? @RheumNow #EULAR2021
Richard Conway @RichardPAConway ( View Tweet )
5 years 2 months ago
Dr Pupim presents data on GM-CSF inhibitor mavrilimumab to treat non-ventilated COVID-19 with systemic hyperinflammation 65% ⬇️ ventilation/death day 29 (p=0.02) 61% ⬇️ death day 29 (p=0.07) @RheumNow #EULAR2021 Abstr#LB0001 https://t.co/VBPyv4Kbv7
Richard Conway @RichardPAConway ( View Tweet )
5 years 2 months ago
Dr Ruperto on secukinumab in ERA and JPsA subtypes of JIA. HR 0.28; 95%CI 0.13–0.63 p<0.001 for flare to week 100. 87.2%, 83.7%, 67.4%, 38.4% and 24.4% of pts achieved JIA ACR 30/50/70/90/100 @RheumNow #EULAR2021 Abstr#LB0004 https://t.co/envFupqqV2
Richard Conway @RichardPAConway ( View Tweet )
5 years 2 months ago
Dr Diekmann presents on rheumatic irAEs in different cancers. More common melanoma than NSCLC. SpA most common. Occurrence associated better tumour response. Good response to immunosuppression @RheumNow #EULAR2021 Abstr#POS0293 https://t.co/0tSHSbRq40
Richard Conway @RichardPAConway ( View Tweet )
5 years 2 months ago
Dr Chatzis presents risk prediction model for MALT lymphoma in Sjogrens. Cryoglobulinaemia and ESSDAI at diagnosis only predictors. AUROC 0.78 for model @RheumNow #EULAR2021 Abstr#POS0290 https://t.co/cLmiMgnpwF
Richard Conway @RichardPAConway ( View Tweet )
5 years 2 months ago
